News | PET Imaging | August 09, 2018

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients

Knowing the heterogeneity of ER expression throughout the body could help guide treatment

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
FIGURE: Distribution of metastases per patient.

FIGURE: Distribution of metastases per patient. Distribution and 18F-FES uptake of all metastases (n=1,617) in 91 individual patients. Bone (blue), lymph node (green), lung (red), breast (pink), brain (orange) and other (purple) lesions are presented. Patients are categorized based on subgroups derived from the cluster analysis. Credit: H.H. Nienhuis et al., University of Groningen, Groningen, The Netherlands

August 9, 2018 — In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the metastases. However, little is known about ER expression across metastases throughout the body and surrounding normal tissue. Using a positron emission tomography (PET) tracer, researchers in the Netherlands have been able to identify differences in ER expression, which could help guide treatment for metastatic breast cancer patients. The study is featured in The Journal of Nuclear Medicine’s August issue.

According to the American Cancer Society, breast cancer is the most common cancer in American women, except for skin cancers, and it is the second leading cause of cancer death for women (following lung cancer). Currently, the U.S. has more than 3.1 million breast cancer survivors, and American women have a 1 in 8 chance of developing breast cancer.

For the study, researchers used fluorine-18-fluoroestradiol (18F-FES) PET to assess ER expression heterogeneity in 91 patients with metastatic breast cancer. 18F-FES uptake was analyzed in 1,617 metastases, as well as in normal tissue.

“The results showed that approximately 50 percent of the patients had one or more estrogen-receptor negative lesions, while the primary tumor was estrogen-receptor positive,” explained Geke A.P. Hospers, M.D., Ph.D., professor of medical oncology at the University of Groningen in The Netherlands. “This heterogeneity of ER expression is, therefore, really common, and it likely affects treatment outcome.”

A higher uptake was found in bone metastases compared to lymph nodes and lung metastases. In addition, in this largest study so far to examine background 18F-FES uptake in the normal tissue surrounding each organ, background uptake was also found to vary per organ, with uptake highest in the skeleton.

Hospers pointed out, “We concluded that 18F-FES uptake in both tumor and normal tissue uptake is heterogeneous and influenced by the site of metastasis. By using cluster analysis on imaging characteristics and metastatic site, three distinct patterns of patients with ER positive metastatic breast cancer were identified.”

She explained the significance, stating, “ER negative lesions will not respond to endocrine treatment, but other ER positive lesions may. The knowledge of this heterogeneity by means of 18F-FES PET may support future specific treatment of metastasis. For example, one ER negative lesion could be treated by radiotherapy, while the endocrine treatment is continued for the other ER positive lesions. The three distinct patterns in ER positive metastatic breast cancer that we identified with our analysis might be useful for future stratification in intervention studies and optimizing personalized treatment.”

For more information: www.jnm.snmjournals.org

Reference

Nienhuis H.H., van Kruchten M., Elias S.G., et al. “18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.” Journal of Nuclear Medicine, March 1, 2018. doi: 10.2967/jnumed.117.198846

Related Content

LOCalizer Implantable Tag Cleared for Long-Term Breast Lesion Placement
Technology | Breast Imaging | January 21, 2019
Hologic announced that the U.S. Food and Drug Administration (FDA) has cleared the LOCalizer radiofrequency...
Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Videos | Interventional Radiology | January 11, 2019
Julius Chapiro, M.D., research faculty member and an...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
AI Approach Outperformed Human Experts in Identifying Cervical Precancer
News | Digital Pathology | January 10, 2019
January 10, 2019 — A research team led by investigators from the National Institutes of Health and Global Good has de
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...